Lexaria Bioscience Corp.(LEXX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-05-31.

Lexaria Bioscience Corp. (LEXX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LEXX at 20.0/100 on a 32-signal composite quality model, placing it at rank #2,783 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Lexaria Bioscience Corp. reports net income of $-2.0M, free cash flow of $-1.6M. Top institutional holders of LEXX by reported 13-F value include Invenomic Capital Management, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. LEXX trades on the Nasdaq exchange and files with the SEC under CIK 1348362. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LEXX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lexaria Bioscience Corp. directly from SEC EDGAR.